[{"id":"91fb4f60-829a-4224-bfce-3668ff6fda2a","acronym":"","url":"https://clinicaltrials.gov/study/NCT04771520","created_at":"2021-02-25T15:52:21.802Z","updated_at":"2025-02-25T14:15:51.905Z","phase":"Phase 2","brief_title":"Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors","source_id_and_acronym":"NCT04771520","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 01/20/2021","start_date":" 01/20/2021","primary_txt":" Primary completion: 12/31/2026","primary_completion_date":" 12/31/2026","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2025-02-17"},{"id":"9f4d4138-2575-46b3-8cf6-894603dcfc63","acronym":"","url":"https://clinicaltrials.gov/study/NCT04908176","created_at":"2021-06-01T17:53:25.780Z","updated_at":"2024-07-02T16:35:07.927Z","phase":"Phase 1","brief_title":"A Drug-drug Interaction Study of Avapritinib and Midazolam","source_id_and_acronym":"NCT04908176","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib) • midazolam hydrochloride"],"overall_status":"Completed","enrollment":" Enrollment 10","initiation":"Initiation: 08/24/2022","start_date":" 08/24/2022","primary_txt":" Primary completion: 03/01/2024","primary_completion_date":" 03/01/2024","study_txt":" Completion: 04/12/2024","study_completion_date":" 04/12/2024","last_update_posted":"2024-04-23"},{"id":"6c758fa1-b102-4d99-aa19-27558b9979c8","acronym":"MegaMOST","url":"https://clinicaltrials.gov/study/NCT04116541","created_at":"2021-01-18T20:07:18.206Z","updated_at":"2024-07-02T16:35:12.639Z","phase":"Phase 2","brief_title":"A Study Evaluating the Activity of Anti-cancer Treatments Targeting Tumor Molecular Alterations/Characteristics in Advanced / Metastatic Tumors.","source_id_and_acronym":"NCT04116541 - MegaMOST","lead_sponsor":"Centre Leon Berard","biomarkers":" KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK","pipe":" | ","alterations":" KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification","tags":["KRAS • BRAF • ALK • FLT3 • NRAS • ROS1 • NTRK2 • HRAS • CDKN2A • NF1 • AXL • CCND1 • CDK4 • PTPN11 • SMAD4 • RAF1 • FLT1 • CDK6 • CCND3 • TYRO3 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KRAS mutation • EGFR mutation • BRAF mutation • NRAS mutation • BRAF V600 • FGFR1 amplification • CDKN2A deletion • HRAS mutation • PTPN11 mutation • CCND1 amplification • KRAS amplification • BRAF amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Mekinist (trametinib) • Tafinlar (dabrafenib) • Alecensa (alectinib) • Cabometyx (cabozantinib tablet) • Stivarga (regorafenib) • Kisqali (ribociclib) • Ayvakit (avapritinib) • siremadlin (HDM201)"],"overall_status":"Recruiting","enrollment":" Enrollment 455","initiation":"Initiation: 01/28/2020","start_date":" 01/28/2020","primary_txt":" Primary completion: 02/01/2026","primary_completion_date":" 02/01/2026","study_txt":" Completion: 11/01/2026","study_completion_date":" 11/01/2026","last_update_posted":"2024-03-27"},{"id":"3b472c71-761b-4c06-a89b-3a6142cd7c02","acronym":"AVIATOR2020","url":"https://clinicaltrials.gov/study/NCT04927260","created_at":"2021-06-15T17:53:23.444Z","updated_at":"2024-07-02T16:35:25.233Z","phase":"","brief_title":"French Long Term Registry With Longitudinal Follow up of PDGFRA D842V-GIST Patients","source_id_and_acronym":"NCT04927260 - AVIATOR2020","lead_sponsor":"Centre Leon Berard","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 03/31/2021","start_date":" 03/31/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2023-12-25"},{"id":"1d571185-66c3-4224-a385-8f3e4c2f1022","acronym":"PATHFINDER","url":"https://clinicaltrials.gov/study/NCT03580655","created_at":"2021-01-18T17:36:58.229Z","updated_at":"2024-07-02T16:35:41.207Z","phase":"Phase 2","brief_title":"(PATHFINDER) Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis","source_id_and_acronym":"NCT03580655 - PATHFINDER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" TMB • KIT","pipe":" | ","alterations":" KIT mutation • KIT D816V","tags":["TMB • KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation • KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 103","initiation":"Initiation: 11/21/2018","start_date":" 11/21/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2026","study_completion_date":" 01/31/2026","last_update_posted":"2023-08-02"},{"id":"2b362821-228e-4647-ab9a-04854ffc8751","acronym":"","url":"https://clinicaltrials.gov/study/NCT05381753","created_at":"2022-05-19T12:57:08.164Z","updated_at":"2024-07-02T16:35:43.571Z","phase":"","brief_title":"Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World","source_id_and_acronym":"NCT05381753","lead_sponsor":"CStone Pharmaceuticals","biomarkers":" KIT","pipe":" | ","alterations":" KIT mutation","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e imatinib • sunitinib • Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 200","initiation":"Initiation: 08/29/2022","start_date":" 08/29/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 10/01/2025","study_completion_date":" 10/01/2025","last_update_posted":"2023-07-10"},{"id":"c402eaa9-bf76-4b0d-b1a4-4b7d8a779eb5","acronym":"BLU-285-3101","url":"https://clinicaltrials.gov/study/NCT04773782","created_at":"2021-02-26T12:55:17.604Z","updated_at":"2024-07-02T16:35:45.622Z","phase":"Phase 1/2","brief_title":"A Study of Avapritinib in Pediatric Patients With Solid Tumors Dependent on KIT or PDGFRA Signaling","source_id_and_acronym":"NCT04773782 - BLU-285-3101","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 02/24/2022","start_date":" 02/24/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/30/2025","study_completion_date":" 04/30/2025","last_update_posted":"2023-06-15"},{"id":"25edff0a-7f77-4f28-8cdb-a05b5d2c6066","acronym":"","url":"https://clinicaltrials.gov/study/NCT05821738","created_at":"2023-04-20T14:03:53.744Z","updated_at":"2024-07-02T16:35:48.599Z","phase":"Phase 2","brief_title":"Avapritinib in CBF-AML With KIT Mutations","source_id_and_acronym":"NCT05821738","lead_sponsor":"The First Affiliated Hospital of Soochow University","biomarkers":" KIT • RUNX1 • RUNX1T1","pipe":" | ","alterations":" KIT mutation","tags":["KIT • RUNX1 • RUNX1T1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 50","initiation":"Initiation: 06/01/2022","start_date":" 06/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-05-09"},{"id":"0b135f3f-be0a-43ad-bf86-0ed39a7b1f3a","acronym":"EXPLORER","url":"https://clinicaltrials.gov/study/NCT02561988","created_at":"2021-01-18T12:24:19.958Z","updated_at":"2024-07-02T16:35:53.073Z","phase":"Phase 1","brief_title":"(EXPLORER) Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies","source_id_and_acronym":"NCT02561988 - EXPLORER","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT","pipe":" | ","alterations":" KIT D816V","tags":["KIT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e KIT D816V"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 86","initiation":"Initiation: 03/10/2016","start_date":" 03/10/2016","primary_txt":" Primary completion: 10/05/2022","primary_completion_date":" 10/05/2022","study_txt":" Completion: 01/19/2023","study_completion_date":" 01/19/2023","last_update_posted":"2023-03-17"},{"id":"b933d773-32a4-4ee6-ab9c-3b71b74aefa7","acronym":"","url":"https://clinicaltrials.gov/study/NCT05464875","created_at":"2022-07-19T14:54:36.704Z","updated_at":"2024-07-02T16:36:07.154Z","phase":"","brief_title":"A Multicenter Study of Avapritinib Efficacy and Safety of Metastatic or Unresectable Gastrointestinal Stromal Tumors","source_id_and_acronym":"NCT05464875","lead_sponsor":"Xinhua Zhang, MD","biomarkers":" ANO1","pipe":"","alterations":" ","tags":["ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/09/2022","start_date":" 07/09/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2022-07-19"},{"id":"9b88117e-7f14-42f3-b2bd-24fb2ea08987","acronym":"","url":"https://clinicaltrials.gov/study/NCT05461664","created_at":"2022-07-18T14:01:34.811Z","updated_at":"2024-07-02T16:36:07.233Z","phase":"","brief_title":"Avapritinib in the Treatment of Unresectable or Recurrent Metastatic GIST Non-exon18 Mutations of PDGFRA","source_id_and_acronym":"NCT05461664","lead_sponsor":"Xinhua Zhang, MD","biomarkers":" ANO1","pipe":"","alterations":" ","tags":["ANO1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Not yet recruiting","enrollment":" Enrollment 74","initiation":"Initiation: 07/10/2022","start_date":" 07/10/2022","primary_txt":" Primary completion: 08/31/2024","primary_completion_date":" 08/31/2024","study_txt":" Completion: 08/31/2024","study_completion_date":" 08/31/2024","last_update_posted":"2022-07-18"},{"id":"beae3831-e867-4796-98b5-a4cab6099ed8","acronym":"NAVIGATOR","url":"https://clinicaltrials.gov/study/NCT02508532","created_at":"2021-01-17T17:33:18.563Z","updated_at":"2024-07-02T16:36:08.544Z","phase":"Phase 1","brief_title":"(NAVIGATOR) Study of BLU-285 in Patients With Gastrointestinal Stromal Tumors (GIST) and Other Relapsed and Refractory Solid Tumors","source_id_and_acronym":"NCT02508532 - NAVIGATOR","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" KIT • PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation","tags":["KIT • PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Completed","enrollment":" Enrollment 250","initiation":"Initiation: 08/01/2015","start_date":" 08/01/2015","primary_txt":" Primary completion: 03/06/2020","primary_completion_date":" 03/06/2020","study_txt":" Completion: 06/03/2021","study_completion_date":" 06/03/2021","last_update_posted":"2022-06-21"},{"id":"28db9516-1c03-4c8b-98d1-37ee5af86d30","acronym":"","url":"https://clinicaltrials.gov/study/NCT03862885","created_at":"2021-01-18T19:03:16.863Z","updated_at":"2024-07-02T16:36:42.722Z","phase":"","brief_title":"Early Access Program (EAP) for Avapritinib in Patients With Locally Advanced Unresectable or Metastatic GIST","source_id_and_acronym":"NCT03862885","lead_sponsor":"Blueprint Medicines Corporation","biomarkers":" PDGFRA","pipe":" | ","alterations":" PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation","tags":["PDGFRA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PDGFRA D842V • PDGFRA mutation • PDGFRA exon 18 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ayvakit (avapritinib)"],"overall_status":"Approved for marketing","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2020-07-27"}]